Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH.
Sanoff HK, et al.
Cancer. 2018 Aug 1;124(15):3118-3126. doi: 10.1002/cncr.31552. Epub 2018 Jun 15.
Cancer. 2018.
PMID: 29905927
Free article.
Clinical Trial.